🇺🇸 Diclofenac, topical in United States
23 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 23
Most-reported reactions
- Dyspnoea — 3 reports (13.04%)
- Hypotension — 3 reports (13.04%)
- Keratopathy — 3 reports (13.04%)
- Blood Creatinine Increased — 2 reports (8.7%)
- Bradycardia — 2 reports (8.7%)
- Condition Aggravated — 2 reports (8.7%)
- Deep Vein Thrombosis — 2 reports (8.7%)
- Diarrhoea — 2 reports (8.7%)
- Drug Interaction — 2 reports (8.7%)
- Fall — 2 reports (8.7%)
Other Pain Management / Rheumatology approved in United States
Frequently asked questions
Is Diclofenac, topical approved in United States?
Diclofenac, topical does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Diclofenac, topical in United States?
Nuvo Research Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.